Samsung Biologics announced on June 8 that it has established a strategic partnership with Pfizer to achieve the long-term commercial production of Pfizer's multi-product portfolio.
Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale production of a multi-product biosimilar portfolio covering oncology, inflammation, and immunology.